Full-Time

Strategic Sourcing Associate Director

Updated on 9/9/2026

Vertex Pharmaceuticals

Vertex Pharmaceuticals

5,001-10,000 employees

Develops therapies for serious genetic diseases

Compensation Overview

$145.6k - $218.4k/yr

+ Annual bonus + Annual equity awards

Company Does Not Provide H1B Sponsorship

Boston, MA, USA

Hybrid

Three days in the Boston office and two days remote per week; occasional travel to other facilities and suppliers is required.

Bachelor's

Category
Operations & Logistics (1)
Required Skills
Power BI
Microsoft Office
ERP
GMP
Financial analysis
Tableau
Risk Management
Data Analysis

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Requirements
  • A minimum of 8–10 years of experience in strategic sourcing, procurement, supplier management, manufacturing support, contract development and manufacturing organization or external partner management, or related experience within the biopharmaceutical industry, with direct exposure to Cell and Gene Therapy raw materials, specialty materials, development and manufacturing support, supplier qualification, or related Cell and Gene Therapy supply categories.
  • A Bachelor's degree in biology, biochemistry, chemistry, chemical engineering, biotechnology, pharmaceutical sciences, supply chain, business, or a related field is preferred.
  • A proven track record of negotiating contracts, managing supplier relationships, and driving cost savings initiatives.
  • Strong analytical and problem-solving skills, with the ability to assess risks and develop effective mitigation strategies.
  • An understanding of raw material specifications, quality requirements, and regulatory standards relevant to current Good Manufacturing Practices.
  • Familiarity with regulatory requirements, quality standards, and best practices in the pharmaceutical industry, including Good Manufacturing Practices and ISO standards.
  • The ability to travel as needed to meet with suppliers, visit manufacturing facilities, and attend industry conferences and events.
  • The ability to influence senior leadership, drive sourcing value, and build trusted stakeholder relationships.
  • Deep understanding of category management and the ability to manage strategic sourcing strategy development, request-for-quote and request-for-proposal execution, negotiation, contract execution, supplier performance management, and business stakeholder management.
  • Expertise in complex supplier negotiations and supplier management activities.
  • Expertise in sourcing, contracting, and managing suppliers that provide critical Cell and Gene Therapy raw materials, specialty materials, technologies, and related manufacturing support services, including supplier governance within internal and external manufacturing environments.
  • Strong analytical capabilities in data analysis and benchmarking research, including experience with data analysis and reporting tools such as Power BI and Tableau.
  • The ability to support sourcing digitization, including artificial intelligence-based sourcing, contracting, supplier intelligence, data analytics, automation, and technology-enabled supplier management processes.
  • Demonstrated use of continuous improvement tools, including Pareto charts and flow diagrams, to drive process improvements.
  • Strong project management and organizational skills.
  • The ability to lead teams collaboratively to drive successful outcomes across business partners, suppliers, Legal, Compliance, Finance, and other functions.
  • Strong written and verbal communication skills, including the ability to articulate opinions concisely and persuasively and speak publicly to audiences including senior management.
  • Strong knowledge of contract law, including terms and conditions, and the ability to provide insight into potential risks across agreements such as confidentiality disclosure agreements and master services agreements.
  • Proficiency in Microsoft Office, strong knowledge of enterprise resource planning systems, and related electronic sourcing tools, including business intelligence and reporting platforms.
  • Excellent communication and interpersonal skills, with the ability to collaborate effectively across functions and organizational levels.
Responsibilities
  • Develop and manage raw materials sourcing categories essential to Cell and Gene Therapy product development and manufacturing.
  • Collaborate with Development, Manufacturing, internal and external manufacturing sites, Quality, Technical Operations, Supply Chain, Finance, Legal, and other functions to define and drive Cell and Gene Therapy raw material category strategies.
  • Manage key strategic suppliers to drive continuous improvement, resolve complex supply issues, and identify value-creation opportunities.
  • Conduct Cell and Gene Therapy raw materials market analysis and due diligence, supplier assessments, request-for-quote and request-for-proposal development, negotiations, competitive price and cost analysis, financial analysis, long-term planning, contract development, supplier management, manufacturing site support, and risk management.
  • Develop strong, trusting, and influential stakeholder relationships, understand business objectives, provide supplier and marketplace expertise, collaborate on strategic and operational plans, and drive business outcomes.
  • Develop and manage category and sourcing strategies, strategic supplier relationships and performance management, and tactical request-for-quote and request-for-proposal activities.
  • Co-develop and implement sourcing strategies with business units, internal manufacturing sites, and external contract manufacturing sites to support Cell and Gene Therapy raw material needs across research, development, clinical manufacturing, commercial manufacturing, lifecycle management, and business continuity.
  • Identify and select critical raw material suppliers and contract development and manufacturing organization partners, negotiate contracts, influence network strategy, and manage supplier relationships.
  • Cultivate and maintain relationships with Cell and Gene Therapy raw material, specialty material, technology, and contract development and manufacturing organization suppliers.
  • Negotiate contracts and agreements to secure favorable terms while aligning with quality, technical, regulatory, and service expectations.
  • Collaborate with suppliers to identify risk mitigation, resilience, cost savings, process improvement, capacity access, technical support, and innovation opportunities.
  • Maintain appropriate supplier governance with external manufacturing, Supply Chain, process development, Quality, and other stakeholders.
  • Assess and mitigate risks related to supplier capacity, quality requirements, regulatory expectations, technical dependencies, manufacturing site needs, and single-source exposures.
  • Develop contingency and resiliency plans to address potential disruptions and ensure continuity of manufacturing supply.
  • Align sourcing activities with Cell and Gene Therapy program needs, production schedules, product specifications, supplier qualification requirements, and regulatory expectations.
  • Conduct market analysis, supplier assessments, and benchmarking to identify opportunities, risks, and strategic partnership models.
  • Implement continuous improvement initiatives to streamline sourcing processes, enhance efficiency, and drive operational excellence.
  • Use data analytics, performance metrics, artificial intelligence-enabled sourcing approaches, supplier intelligence, automation, and technology-enabled tools to monitor supplier performance and improve decision-making.
  • Support the annual budget process, provide cost guidance for Long Range Planning, and evaluate bills of material and total cost of goods to identify opportunities and risks.
Desired Qualifications
  • Working knowledge of artificial intelligence-based sourcing, contracting, supplier intelligence, data analytics, automation, or other technology-enabled sourcing approaches.
  • In-depth knowledge of Cell and Gene Therapy raw material requirements, supplier qualification considerations, manufacturing processes, development pathways, commercial product support, quality expectations, and relevant material technology needs.
  • An advanced degree or relevant professional certifications.
Vertex Pharmaceuticals

Vertex Pharmaceuticals

View

Vertex Pharmaceuticals develops medicines for serious diseases, with a focus on cystic fibrosis. It conducts extensive research and partners with other biotech firms to discover and develop new therapies, including ex vivo engineered cell treatments. Its products, such as ivacaftor, treat cystic fibrosis and other therapies undergo clinical testing to expand the pipeline. Revenue comes from selling approved drugs and from licensing and collaboration agreements. The company distinguishes itself through deep R&D investment, strategic partnerships, and a global reach aimed at addressing unmet medical needs. The overall goal is to bring effective new drugs to patients worldwide and improve outcomes and quality of life.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

Boston, Massachusetts

Founded

1989

Get referred to Vertex Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • On August 3, 2026, Vertex raised 2026 revenue guidance to $13.1 billion-$13.2 billion.
  • Povetacicept's November 30, 2026 PDUFA supports a potential IgA nephropathy launch.
  • CASGEVY reached pediatric approval in August 2026, broadening sickle-cell and thalassemia demand.

What critics are saying

  • On August 24, 2026, Judge Bibas cleared Lupin's generic Kalydeco path.
  • Vertex discontinued VX-522 in 2026 after lung inflammation ended its CF mRNA program.
  • If CF pricing weakens before replacements mature, Vertex's revenue engine cracks by 2028.

What makes Vertex Pharmaceuticals unique

  • Vertex still treats nearly 95% of core-market cystic fibrosis patients.
  • Its September 1, 2026 Crinetics deal adds rare endocrine commercialization and Phase 3 depth.
  • Vertex converts biology leadership into cash, funding pipeline expansion without immediate dilution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

8%

2 year growth

8%
Lifescience Intellipedia Pvt. Ltd.
Sep 2nd, 2026
Vertex completes $10 billion acquisition of Crinetics Pharmaceuticals.

Vertex completes $10 billion acquisition of Crinetics Pharmaceuticals. Deal expands Vertex into rare endocrine diseases. Vertex Pharmaceuticals has completed its acquisition of Crinetics Pharmaceuticals, strengthening its presence in endocrine diseases and adding new commercial and clinical-stage medicines to its portfolio. The acquisition was completed on September 1, 2026, after receiving the required regulatory clearances and approval from Crinetics shareholders. Vertex had announced the definitive agreement on July 6, 2026. Under the deal, Vertex agreed to acquire Crinetics for a total equity value of approximately $10.0 billion. After accounting for estimated cash acquired, the transaction has a net value of approximately $8.8 billion. The acquisition gives Vertex access to PALSONIFY (paltusotine), an approved oral treatment for acromegaly, as well as atumelnant, an investigational treatment being developed for congenital adrenal hyperplasia and Cushing's syndrome. Vertex expects the acquisition to support revenue growth, expand its innovation pipeline, and strengthen its long-term earnings profile. PALSONIFY becomes part of Vertex's commercial portfolio. One of the biggest additions from the Crinetics acquisition is PALSONIFY. PALSONIFY is a once-daily oral therapy for acromegaly and is currently the only treatment of its kind approved for this use. The medicine has already been launched in the United States and approved in the European Union. It is also under regulatory review in other markets around the world. Acromegaly is a rare endocrine disorder that occurs when the body produces too much growth hormone. The excess hormone can cause abnormal growth of bones and tissues and may lead to serious health complications if left untreated. With PALSONIFY now part of Vertex's portfolio, the company plans to continue expanding the medicine globally. Atumelnant adds a new late-stage pipeline program. The acquisition also brings Atumelnant into Vertex's development pipeline. Atumelnant is a once-daily oral adrenocorticotropic hormone, or ACTH, receptor antagonist. The medicine is currently being studied in Phase 3 clinical development for congenital adrenal hyperplasia, also known as CAH. It is also being evaluated in Phase 2 development for Cushing's syndrome. Congenital adrenal hyperplasia is a group of inherited disorders that affect the adrenal glands and can interfere with the body's production of certain hormones. Cushing's syndrome occurs when the body is exposed to excessive levels of cortisol over an extended period. Atumelnant could give Vertex another opportunity to develop oral treatments for rare endocrine diseases. Combined revenue potential of more than $5 billion. Vertex expects PALSONIFY and Atumelnant to have significant commercial potential. At peak sales, the two medicines are expected to generate more than $5 billion in combined annual revenue. The company also expects the acquisition to become accretive to non-GAAP operating income in 2029. The financial impact of the acquisition will be reported in more detail as Vertex provides its third-quarter financial results. The transaction is being accounted for as a business combination. Vertex plans to provide additional information about the accounting treatment and financial impact during its third-quarter earnings call scheduled for November 2, 2026. Rare endocrine diseases become a new growth area. The Crinetics acquisition adds rare endocrine diseases as a new major area of focus for Vertex. The company already has four established areas of focus: cystic fibrosis, hematology, acute pain, and renal diseases. Rare endocrine diseases will now become another pillar of Vertex's growth strategy. This expands the company's business beyond its traditional areas while giving it access to an established endocrine medicine and additional late-stage research programs. Vertex expands its executive leadership team. Along with completing the Crinetics acquisition, Vertex announced several changes to its executive leadership team. Charles Wagner, Vertex's executive vice president and chief operating and financial officer, will immediately take on additional responsibility for leading the integration of Crinetics. Wagner will continue serving as Vertex's chief operating officer while overseeing the integration of the newly acquired company. His expanded role is expected to help Vertex bring Crinetics' operations, employees, products, and development programs into the broader Vertex organization. Jonathan Poole to become chief financial officer. Vertex also announced that Jonathan Poole will become executive vice president and chief financial officer effective January 1, 2027. Poole currently serves as Vertex's senior vice president of finance. He has led Vertex's global finance organization since March 2020 and has been involved during a period of major expansion for the company. During his time at Vertex, Poole has supported the expansion of the company's research and development pipeline, global commercial operations, business diversification, and several acquisitions. In his new role, Poole will report directly to Reshma Kewalramani, M.D., Vertex's chief executive officer and president. He will also join the company's Executive Committee. Poole Brings Extensive Biopharma Finance Experience Before joining Vertex, Poole held several senior finance positions in the biopharmaceutical industry. He previously served as chief financial officer of Evelo Biosciences and Genocea Biosciences. He also served as senior vice president of finance at Shire Plc. His experience includes financial leadership during periods of business growth, portfolio development, and corporate transactions. At Vertex, he will take over the CFO role while Wagner continues in his expanded position as chief operating officer. Jasper van Grunsven to Lead Pain and New Product Planning Vertex is also adding Jasper van Grunsven to its executive leadership team. Van Grunsven will join Vertex on September 8, 2026, as executive vice president, chief of pain, and new product planning officer. He will be responsible for Vertex's pain franchise, including JOURNAVX (suzetrigine), which is approved for moderate-to-severe acute pain. He will also oversee global new product planning. Van Grunsven will report to Dr. Kewalramani and become a member of the Vertex Executive Committee. Van Grunsven Brings Global Commercial Experience Van Grunsven has experience across sales, marketing, and business operations in different countries, disease areas, and treatment technologies. Most recently, he served as senior vice president of Amgen's Rare Disease portfolio and its Global Customer Capabilities Data & Analytics function. Before Amgen, he held a number of roles with increasing responsibility at AbbVie, Abbott Laboratories, and Nycomed. Vertex said his experience will support the company's growing pain business and its plans for future product launches. Vertex Looks to Its Next Phase of Growth Vertex CEO and President Reshma Kewalramani said the company is entering a new phase of growth and diversification as its research pipeline and commercial portfolio continue to expand. She welcomed the Crinetics team to Vertex and said the company will work to continue the global launch of PALSONIFY while accelerating the development of atumelnant. The company also highlighted the expanded responsibilities of Wagner and Poole and the addition of van Grunsven to the leadership team. Vertex's Broader Pipeline Continues to Expand The Crinetics acquisition is part of a broader strategy by Vertex to develop medicines across serious diseases where the company believes it has strong knowledge of human biology. Vertex currently has approved therapies for conditions including cystic fibrosis, sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and acromegaly. The company also has a clinical pipeline covering several other diseases. These programs include treatments being investigated for IgA nephropathy, neuropathic pain, APOL1-mediated kidney disease, primary membranous nephropathy, congenital adrenal hyperplasia, ACTH-dependent Cushing's syndrome, autosomal dominant polycystic kidney disease, type 1 diabetes, generalized myasthenia gravis, and myotonic dystrophy type 1. The company's research programs also cover several different treatment approaches and technology platforms. Vertex Adds Another Commercial Medicine With the completion of the Crinetics acquisition, Vertex now has PALSONIFY as an additional commercial product. The medicine expands Vertex's presence in rare endocrine diseases and provides the company with an already launched product that can be developed further in international markets. At the same time, atumelnant gives Vertex a late-stage development program that could potentially add another important endocrine medicine to its portfolio. The combination of an established commercial product, a Phase 3 program, and earlier pipeline assets gives Vertex a broader position in endocrine diseases. About Vertex Pharmaceuticals Vertex Pharmaceuticals is a global biotechnology company focused on developing medicines for serious diseases and conditions. The company was founded in 1989 and is headquartered in Boston, with its international headquarters in London. Vertex has research and development locations and commercial offices across North America, Europe, Australia, Latin America, and the Middle East. The company has built its business around scientific research and the development of medicines designed to address serious diseases. With the completion of the Crinetics acquisition, Vertex is adding rare endocrine diseases to its existing focus areas while expanding its commercial portfolio, clinical pipeline, and global operations.

Yahoo Finance
Aug 31st, 2026
Vertex Pharmaceuticals shows promise while GE HealthCare and Wells Fargo face challenges

Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.

Yahoo Finance
Aug 26th, 2026
Vertex Pharmaceuticals up 15% in a month on strong Q2 results and raised guidance

Vertex Pharmaceuticals' stock has climbed 15.4% in a month, buoyed by strong second-quarter results and an improved outlook. The company reported revenues of $3.33 billion, up 12% year over year, and raised its full-year guidance to $13.1–$13.2 billion. Vertex's cystic fibrosis (CF) products generated $6.1 billion in the first half of 2026, growing 8.4% year over year. Its newest CF medicine, Alyftrek, performed particularly well, with second-quarter sales of $573.6 million, up 35% sequentially. The drug surpassed $1 billion in cumulative global revenues in the first half of the year. Vertex holds a leadership position in CF, treating nearly 95% of patients in core markets, with no near-term competitive threats. Label expansions and launches in new geographies are expected to drive continued growth.

Ticker Report
Aug 19th, 2026
Wealthfront Advisers LLC Makes New $20.67 Million Investment in Vertex Pharmaceuticals Incorporated $VRTX

Wealthfront Advisers LLC acquired a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 41,608 shares of the pharmaceutical company’s stock, valued at approximately $20,668,000. Other hedge funds also recently […]

Yahoo Finance
Aug 14th, 2026
Vertex Pharmaceuticals hits all-time high despite CF competition risks

Vertex Pharmaceuticals recently hit an all-time high after bouncing back from recent setbacks. The biotech continues dominating the cystic fibrosis (CF) market with no meaningful competition, generating $3.2 billion in CF revenue last quarter. Second-quarter sales reached $3.33 billion, up 12% year-over-year, whilst earnings per share rose 8% to $4.31. Several competitors have attempted to challenge Vertex's CF dominance, but most have failed. Sionna Therapeutics' leading CF candidate recently flopped in mid-stage trials, whilst AbbVie previously abandoned its CF programmes. Beyond CF, Vertex is expanding into new areas. The company expects $500 million in non-CF revenue by 2026. Its gene editing treatment Casgevy recently earned approval for children as young as two, whilst non-opioid pain medicine Journavx could gain additional indications.